Celebrex - Cervix: Celecoxib in the Treatment of Patients With Locally Advanced Carcinoma of the Cervix

Inclusion Criteria: * Biopsy-proven carcinoma of the cervix, with visible/palpable tumours; FIGO stage T1B-3B, NO/1, MO, to be treated with definitive radiotherapy and chemotherapy * ECOG performance status of 0, 1, or 2 * Adequate hematologic function; Granulocyte count greater than 1.5 x 109/L, Platelet count greater than 100 x 109/L * Adequate organ function; Serum creatinine £ 1.25 x ULN, or a calculated creatinine clearance ³ 50 mL/min, Serum bilirubin £ 1.25 x ULN and AST/ALT £ 3xULN * No prior treatment for cervix cancer * Informed consent Exclusion Criteria: * Use of an NSAID in the 2 weeks prior to study enrollment * Patients with an active malignancy at another site * Patients with significant cardiac, renal, or pulmonary disease or any other medical conditions that may preclude radical therapy * Patients who have significant history of ischaemic heart disease or stroke who would be deemed not suitable for cessation of their daily prophylactic aspirin * Patients with history of peptic ulcer disease or previous NSAID related gastrointestinal bleeding * Patients with hypersensitivity to NSAIDS or celecoxib, or sulfonamides * Patients who unwilling or unable to give informed consent